Stock Track | Amneal Pharmaceuticals Plummets 5.04% Intraday Despite Q4 Beat as 2026 Revenue Guidance Disappoints

Stock Track02-28

Amneal Pharmaceuticals Inc. (NASDAQ: AMRX) saw its shares plummet 5.04% during intraday trading on Friday. The sharp decline came despite the company reporting better-than-expected financial results for the fourth quarter of 2025.

The generic and specialty drug maker announced Q4 adjusted earnings of $0.21 per share, beating the Wall Street consensus estimate of $0.18. Revenue for the quarter reached $814.3 million, also exceeding analyst expectations of $807.9 million and marking an 11% increase year-over-year.

However, investor sentiment turned negative as the company issued its financial outlook for 2026. Amneal guided for full-year revenue in the range of $3.05 billion to $3.15 billion, which fell short of the FactSet consensus estimate of $3.21 billion. While the company's adjusted EPS guidance of $0.93 to $1.03 was roughly in line with the $0.94 estimate, the weaker revenue forecast appears to have driven the sell-off as traders reacted to the company's projected growth trajectory.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1124700473?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-28 02:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1124700473","market":"nz","top_or_hot":-1,"title":"Stock Track | Amneal Pharmaceuticals Plummets 5.04% Intraday Despite Q4 Beat as 2026 Revenue Guidance Disappoints","media":"Stock Track","content":"<p>Amneal Pharmaceuticals Inc. (NASDAQ: AMRX) saw its shares plummet 5.04% during intraday trading on Friday. The sharp decline came despite the company reporting better-than-expected financial results for the fourth quarter of 2025.</p><p>The generic and specialty drug maker announced Q4 adjusted earnings of $0.21 per share, beating the Wall Street consensus estimate of $0.18. Revenue for the quarter reached $814.3 million, also exceeding analyst expectations of $807.9 million and marking an 11% increase year-over-year.</p><p>However, investor sentiment turned negative as the company issued its financial outlook for 2026. Amneal guided for full-year revenue in the range of $3.05 billion to $3.15 billion, which fell short of the FactSet consensus estimate of $3.21 billion. While the company's adjusted EPS guidance of $0.93 to $1.03 was roughly in line with the $0.94 estimate, the weaker revenue forecast appears to have driven the sell-off as traders reacted to the company's projected growth trajectory.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Amneal Pharmaceuticals Plummets 5.04% Intraday Despite Q4 Beat as 2026 Revenue Guidance Disappoints</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Amneal Pharmaceuticals Plummets 5.04% Intraday Despite Q4 Beat as 2026 Revenue Guidance Disappoints\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-28 02:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Amneal Pharmaceuticals Inc. (NASDAQ: AMRX) saw its shares plummet 5.04% during intraday trading on Friday. The sharp decline came despite the company reporting better-than-expected financial results for the fourth quarter of 2025.</p><p>The generic and specialty drug maker announced Q4 adjusted earnings of $0.21 per share, beating the Wall Street consensus estimate of $0.18. Revenue for the quarter reached $814.3 million, also exceeding analyst expectations of $807.9 million and marking an 11% increase year-over-year.</p><p>However, investor sentiment turned negative as the company issued its financial outlook for 2026. Amneal guided for full-year revenue in the range of $3.05 billion to $3.15 billion, which fell short of the FactSet consensus estimate of $3.21 billion. While the company's adjusted EPS guidance of $0.93 to $1.03 was roughly in line with the $0.94 estimate, the weaker revenue forecast appears to have driven the sell-off as traders reacted to the company's projected growth trajectory.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AMRX","symbol_name":"Amneal Pharmaceuticals, Inc.","start_time":0,"source_url":"","article_id":"1124700473","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1124700473","pubTimestamp":1772218557,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Amneal Pharmaceuticals Inc. (NASDAQ: AMRX) saw its shares plummet 5.04% during intraday trading on Friday. The sharp decline came despite the company reporting better-than-expected financial results...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AMRX":"Amneal Pharmaceuticals, Inc."},"translate_title":"个股追踪|Amneal Pharmaceuticals尽管第四季度业绩好于2026年营收指引令人失望，但盘中暴跌5.04%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMRX":1},"content_text":"Amneal Pharmaceuticals Inc. (NASDAQ: AMRX) saw its shares plummet 5.04% during intraday trading on Friday. The sharp decline came despite the company reporting better-than-expected financial results for the fourth quarter of 2025.The generic and specialty drug maker announced Q4 adjusted earnings of $0.21 per share, beating the Wall Street consensus estimate of $0.18. Revenue for the quarter reached $814.3 million, also exceeding analyst expectations of $807.9 million and marking an 11% increase year-over-year.However, investor sentiment turned negative as the company issued its financial outlook for 2026. Amneal guided for full-year revenue in the range of $3.05 billion to $3.15 billion, which fell short of the FactSet consensus estimate of $3.21 billion. While the company's adjusted EPS guidance of $0.93 to $1.03 was roughly in line with the $0.94 estimate, the weaker revenue forecast appears to have driven the sell-off as traders reacted to the company's projected growth trajectory.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1124700473","isCrawlerRequest":true}